Overview

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Status:
Not yet recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

Evaluation of the potential incremental efficacy and safety of inavolisib in the neoadjuvant endocrine treatment of early-stage HER2-positive, HR-positive, PIK3CA mutant breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

German Breast Group

Collaborator:

Roche Pharma AG